Antitumor effect of endostatin overexpressed in C6 glioma cells is associated with the down-regulation of VEGF

International Journal of Oncology

Volumn 38, Issue 2, 2011, Pages 465-471

  Yang, Lijuan ^a   Lin, Zhixiong ^a   Lin, Jianhua ^a   Weng, Shenmei ^a   Huang, Qian ^b   Zhang, Pengfei ^a   Fu, Jin ^c,d  

^a FUJIAN MEDICAL UNIVERSITY   (China)

^b SUZHOU UNIVERSITY   (China)

^c XIAMEN UNIVERSITY   (China)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Angiogenesis; Anti angiogenic agent; Endostatin; Glioma; Vascular endothelial growth factor

Indexed keywords

ENDOSTATIN; VASCULOTROPIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; DOWN REGULATION; GENE OVEREXPRESSION; GLIOBLASTOMA; IMMUNOHISTOCHEMISTRY; MALE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; RAT; TUMOR CELL;

ADENOCARCINOMA; ANGIOGENESIS INHIBITORS; ANIMALS; APOPTOSIS; BLOTTING, WESTERN; BRAIN NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; DOWN-REGULATION; ENDOSTATINS; GENE EXPRESSION; GENETIC VECTORS; GLIOBLASTOMA; IMMUNOENZYME TECHNIQUES; LUNG NEOPLASMS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; ORGANOPHOSPHORUS COMPOUNDS; RATS; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 78651228206     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2010.871     Document Type: Article

References (28)

1. Folkman J: Role of angiogenesis in tumor growth and metastasis. Semin Oncol 29 (6 Suppl. 16): 15-18, 2002.
2. Verhoeff JJ, van Tellingen O, Claes A, et al: Concerns about anti-angiogenic treatment in patients with glioblastoma multiforme. BMC Cancer 9: 444-453, 2009.
3. Pluda JM: Tumor-associated angiogenesis: mechanisms, clinical implications, and therapeutic strategies. Semin Oncol 24: 203-218, 1997.
4. Vecchiarelli-Federico LM, Cervi D, Haeri M, Li Y, Nagy A and Ben-David Y: Vascular endothelial growth factor - a positive and negative regulator of tumor growth. Cancer Res 70: 863-867, 2010.
5. Nyberg P, Salo T and Kalluri R: Tumor microenvironment and angiogenesis. Front Biosci 13: 6537-6553, 2008.
6. Joki T, Machluf M, Atala A, et al: Continuous release of endostatin from microencapsulated engineered cells for tumor therapy. Nat Biotechnol 19: 35-39, 2001.
7. Read TA, Sorensen DR, Mahesparan R, et al: Local endostatin treatment of gliomas administered by microencapsulated producer cells. Nat Biotechnol 19: 29-34, 2001.
8. Ma HI, Lin SZ, Chiang YH, et al: Intratumoral gene therapy of malignant brain tumor in a rat model with angiostatin delivered by adeno-associated viral (AAV) vector. Gene Ther 9: 2-11, 2002.
9. O'Reilly MS, Boehm T, Shing Y, et al: Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 88: 277-285, 1997.
10. Shichiri M and Hirata Y: Antiangiogenesis signals by endostatin. FASEB J 15: 1044-1053, 2001.
11. Dhanabal M, Ramchandran R, Waterman MJ, et al: Endostatin induces endothelial cell apoptosis. J Biol Chem 274: 11721-11726, 1999.
12. Zheng MJ: Endostatin derivative angiogenesis inhibitors. Chin Med J 122: 1947-1951, 2009.
13. Ratel D, Nasser V, Dupre I, Benabid AL and Berger F: Antibodies to endostatin in a multifocal glioblastoma patient. Lancet 356: 1656-1657, 2000.
14. Morimoto T, Aoyagi M, Tamaki M, et al: Increased levels of tissue endostatin in human malignant gliomas. Clin Cancer Res 8: 2933-2938, 2002.
15. Lin ZX, Yang LJ, Huang Q, et al: Inhibition of tumor-induced edema by antisense VEGF is mediated by suppressive vesiculovacuolar organelles (VVO) formation. Cancer Sci 99: 2540-2546, 2008.
16. Weidner N, Folkman J, Pozza F, et al: Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma. J Natl Cancer Inst 84: 1875-1887, 1992.
17. Chodorowska G, Chodorowski J and Wysokinski A: Vascular endothelial growth factor (VEGF) in physiological and pathological cinditions. Ann Univ Mariae Curie Sklodowska Med 59: 8-14, 2004.
18. Gilbertson RJ and Rich JN: Making a tumor's bed glioblastoma stem cells and the vascular niche. Nat Rev Cancer 7: 733-736, 2007.
19. Boehm T, Folkman J, Browder T and O'Reilly MS: Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 390: 404-407, 1997.
20. Blezinger P, Wang J, Gondo M, et al: Systemic inhibition of tumor growth and tumor metastases by intramuscular administration of the endostatin gene. Nat Biotechnol 17: 343-348, 1999. (Pubitemid 29166035)
21. Eisterer W, Jiang X, Bachelot T, et al: Unfulfilled promise of endostatin in a gene therapy-xenotransplant model of human acute lymphocytic leukemia. Mol Ther 5: 352-359, 2002.
22. Chen QR, Kumar D, Stass SA and Mixson AJ: Liposomes complexed to plasmids encoding angiostatin and endostatin inhibit breast cancer in nude mice. Cancer Res 59: 3308-3312, 1999.
23. Kisker O, Becker CM, Prox D, et al: Continuous administration of endostatin by intraperitoneally implanted osmotic pump improves the efficacy and potency of therapy in a mouse xenograft tumor model. Cancer Res 61: 7669-7674, 2001.
24. Peroulis I, Jonas N and Saleh M: Antiangiogenic activity of endostatin inhibits C6 glioma growth. Int J Cancer 97: 839-845, 2002.
25. Harrigan MR: Angiogenic factors in the central nervous system. Neurosurgery 53: 639-660, 2003.
26. Verheul HM, Hammers H, van Erp K, et al: Vascular endothelial growth factor trap blocks tumor growth, metastasis formation, and vascular leakage in an orthotopic murine renal cell cancer model. Clin Cancer Res 13: 4201-4208, 2007.
27. Yamaguchi N, Anand-Apte B, Lee M, et al: Endostatin inhibits VEGF-induced endothelial cell migration and tumor growth independently of zinc binding. EMBO J 18: 4414-4423, 1999.
28. Karumanchi SA, Jha V, Ramchandran R, et al: Cell surface glypicans are low-affinity endostatin receptors. Mol Cell 7: 811-822, 2001.